2012 NET SALES
Longjumeau, 24 January 2013
Net sales up 5.9% in 2012
| (in thousands of euros) | 2010 | 2011 | 2012 | % change |
| Total as of 31 December | 158 511 | 164 544 | 174 289 | 5,9% |
| including Pharmaceutical Synthesis | 99 379 | 102 096 | 110 001 | 7,7% |
| including Fine Speciality Chemicals | 59 132 | 62 448 | 64 288 | 2,9% |
The PCAS Group achieved 5.9% growth in consolidated net sales for 2012 compared with 2011.
Pharmaceutical Synthesis
Net sales are up 7.7% for 2012 compared with 2011, driven by activities based on proprietary technological platforms.
Fine Specialty Chemicals
The Fine Specialty Chemicals business has continued to grow (+2.9% in 2012 versus 2011), despite confirmation of the Fragrance business underperforming.
In view of this increase in sales, it is possible, as of now, to confirm a significant growth in current operating income for 2012 in relation to 2011.
Next date: 2012 results on 20 February 2013
About PCAS :
Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.
